Generalized Pustular Psoriasis (GPP) (DBCOND0077543)

Identifiers

Synonyms

Generalized Pustular Psoriasis / Impetigo herpetiformis / Generalized pustular psoriasis (disorder)

Associated Data

Indicated Drugs and Targets

Drug	Description	Targets
Spesolimab	An interleukin-36 receptor antagonist used to treat generalized pustular psoriasis flares in adults.	Interleukin-1 receptor-like 2target

Clinical Trials

Identifier	Title	Drug(s)	Purpose	Phase	Status
NCT05200247	An Expanded Access Trial in Japan to Provide Spesolimab to People With a Flare-up in Generalized Pustular Psoriasis Who Have no Other Treatment Options	Spesolimab	treatment	3	completed
NCT05352893	Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Subjects With GPP	Imsidolimab	treatment	3	completed
NCT04566471	Palmoplantar Pustulosis and Generalized Pustular Psoriasis: A National Population-based Analysis of Prevalence	No drug interventions	Not Available	Not Available	unknown_status
NCT06323356	A Study of TAK-279 in Adult Participants With Generalized Pustular Psoriasis or Erythrodermic Psoriasis	Zasocitinib	treatment	3	recruiting
NCT06477536	Long-Term Safety and Efficacy of HB0034 in Subjects With Generalized Pustular Psoriasis	No drug interventions	treatment	2 / 3	not_yet_recruiting
NCT06391996	Biologic Therapy for Generalized Pustular Psoriasis	Secukinumab Ustekinumab	Not Available	Not Available	completed
NCT05239039	An Expanded Access Program in China to Provide Spesolimab to People With a Flare-up in Generalized Pustular Psoriasis Who Have no Other Treatment Options	Spesolimab	treatment	3	completed
NCT03782792	Effisayil™ 1: A Study to Test Spesolimab (BI 655130) in Patients With a Flare-up of a Skin Disease Called Generalized Pustular Psoriasis	Spesolimab	treatment	2	completed
NCT06013969	A Study to Test Whether Spesolimab Helps People With Generalized Pustular Psoriasis (GPP) Who Need Treatment for Repeated Flares	Spesolimab	treatment	4	recruiting
NCT05512598	HB0034 in Patients With Generalized Pustular Psoriasis (GPP)	No drug interventions	treatment	1	completed
NCT04399837	A Study to Test Whether BI 655130 (Spesolimab) Prevents Flare-ups in Patients With Generalized Pustular Psoriasis	Spesolimab	treatment	2	completed
NCT03942042	A Study of Ixekizumab (LY2439821) in Participants in Japan With Generalized Pustular Psoriasis and Erythrodermic Psoriasis	Ixekizumab	treatment	4	completed
NCT06433531	A Clinical Study of TQH2929 Injection in Treatment With Generalized Pustular Psoriasis (GPP)	No drug interventions	treatment	1	recruiting
NCT06100991	CorEvitas Generalized Pustular Psoriasis (GPP) Drug Safety and Effectiveness Registry	No drug interventions	Not Available	Not Available	recruiting
NCT06295692	A Study of JNJ-77242113 for the Treatment of Participants With Generalized Pustular Psoriasis or Erythrodermic Psoriasis	No drug interventions	treatment	3	recruiting
NCT03886246	Effisayil™ ON: A Study to Test Long-term Treatment With Spesolimab in People With Generalized Pustular Psoriasis Who Took Part in a Previous Study	Spesolimab	treatment	2	active_not_recruiting
NCT05366855	Long-Term Safety and Efficacy of Imsidolimab (ANB019) in Subjects With Generalized Pustular Psoriasis	Imsidolimab	treatment	3	terminated
NCT05670821	PMS of Spesolimab I.V. in GPP Patients With Acute Symptoms	Spesolimab	Not Available	Not Available	recruiting
NCT03619902	A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in Adults With Generalized Pustular Psoriasis	Imsidolimab	treatment	2	completed
NCT02533375	Study to Investigate Efficacy and Safety of Adalimumab in Japanese Subjects With Generalized Pustular Psoriasis (GPP)	Adalimumab	treatment	3	completed
NCT06231381	Efficacy and Safety of HB0034 in Patients With Generalized Pustular Psoriasis (GPP)	No drug interventions	treatment	2	recruiting